Fusion Antibodies

Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.

Fusion provides contract services include...

- Antibody Humanization services

- Antibody Engineering Services

- Antibody sequencing Services

- Protein Expression & Purification Services

- Monoclonal Antibody services BLAST & Standard

- cGMP Services

Fusion Therapeutics (a division of Fusion Antibodies) is committed to developing therapeutic antibodies and recombinant proteins to disease specific markers. Fusion Therapeutics is primarily focused on the key areas of oncology and angiogenesis where immunotherapeutic intervention has a proven track record. The company’s genomic mining and proteomic discovery strategy has resulted in the development of a growing pipeline of candidate drugs. Fusion Antibodies have a number of exciting targets undergoing validation with two targets currently in preclinical trials.

Company Growth (employees)
Dunmurry, GB
Size (employees)
20 (est)+6%
Fusion Antibodies was founded in 2001 and is headquartered in Dunmurry, GB

Fusion Antibodies Office Locations

Fusion Antibodies has an office in Dunmurry
Show all (1)

Fusion Antibodies Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$2.5 m

Latest funding size

$2.5 m

Time since last funding

over 10 years


Fusion Antibodies's latest funding round in July 2007 was reported to be $2.5 m. In total, Fusion Antibodies has raised $2.5 m

Fusion Antibodies Financials

Fusion Antibodies's revenue was reported to be £1.9 m in FY, 2017 which is a 29% increase from the previous period.

Revenue (FY, 2017)

1.9 m

Gross profit (FY, 2017)

961.5 k

Gross profit margin (FY, 2017), %


Net income (FY, 2017)

120 k

EBITDA (FY, 2017)

159.5 k

EBIT (FY, 2017)

126.5 k

Cash (31-Mar-2017)

285.7 k
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2016FY, 2017

Net Income

(815.8 k)(1.1 m)(1.3 m)(960.2 k)(533.9 k)(752.2 k)(468.7 k)(113.5 k)1.2 m120 k

Cash From Operating Activities

346.6 k(37.4 k)

Cash From Financing Activities


Net Change in Cash

310.3 k(128.3 k)
    GBPY, 2017


    148.2 k

    Financial Leverage

    1.3 x
    Show all financial metrics

    Fusion Antibodies's Web-traffic and Trends

    Fusion Antibodies Online and Social Media Presence

    Fusion Antibodies Company Life and Culture

    You may also be interested in